AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22572602 — intervention group
Group type: COMPARATOR
Intervention: Baseline levels of MDG-related spending
Number of subjects: 0
Study 22573483 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 633
Study 22573483 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of RAAS blockade and diuretics
Number of subjects: 633
Study 22573483 — intervention group
Group type: EXPERIMENTAL
Intervention: Two or more diuretics
Number of subjects: 633
Study 22573483 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop diuretics
Number of subjects: 633
Study 22573483 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with diuretics and RAAS blockade
Number of subjects: 633
Study 22574715 — intervention group
Group type: EXPERIMENTAL
Intervention: In-patient treatment program based on physical exercise and a balanced diet
Number of subjects: 32
Study 22574715 — intervention group
Group type: COMPARATOR
Intervention: Control group of 15 teenagers
Number of subjects: 32
Study 22576262 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset RA
Number of subjects: 0
Study 22576262 — intervention group
Group type: COMPARATOR
Intervention: Chronic RA
Number of subjects: 0
Study 22576262 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 22576262 — intervention group
Group type: EXPERIMENTAL
Intervention: P gingivalis
Number of subjects: 0
Study 22576262 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaeroglobus geminatus
Number of subjects: 0
Study 22576262 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevotella and Leptotrichia species
Number of subjects: 0
Study 22576338 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI regimen (irinotecan 180 mg/m² i.v. on day 1, leucovorin 200 mg/m² i.v. on days 1 and 2, 5-FU 400 mg/m² i.v. bolus on days 1 and 2, and 5-FU 600 mg/m² i.v. by ci for 22 h on days 1 and 2, repeated every 2 weeks)
Number of subjects: 50
Study 22577154 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA) treatment
Number of subjects: 77
Study 22577154 — intervention group
Group type: EXPERIMENTAL
Intervention: BCL2L10 knockdown
Number of subjects: 77
Study 22577154 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of BCL2L10 expressing cells (assessed by flow cytometry)
Number of subjects: 77
Study 22577154 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of BCL2L10 positive bone marrow cells
Number of subjects: 77
Study 22578085 — intervention group
Group type: EXPERIMENTAL
Intervention: EMR-based clinical decision support (CDS)
Number of subjects: 1092
Study 22578085 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1092
Study 22579160 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent treatment with tapering and discontinuation of risperidone long-acting injection over 6 weeks, followed by reinstitution of oral risperidone or risperidone long-acting injection upon symptom recurrence.
Number of subjects: 33
Study 22579160 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned, but refers to the absence of continuous treatment after 2 years.
Number of subjects: 33
Study 22580120 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation therapy (54 Gy, 5-fluouracil-based)
Number of subjects: 91
Study 22580120 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease between early (1 h) and late (3 h) SUVmax at 6-week PET/CT
Number of subjects: 91
Study 22580254 — intervention group
Group type: EXPERIMENTAL
Intervention: Offline fusion of co-registered IVUS and OCT images
Number of subjects: 9
Study 22580941 — intervention group
Group type: EXPERIMENTAL
Intervention: Reoperation after primary umbilical/epigastric hernia repair
Number of subjects: 902
Study 22580941 — intervention group
Group type: EXPERIMENTAL
Intervention: Reoperation after incisional hernia repair
Number of subjects: 902
Study 22580941 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall recurrence after primary umbilical/epigastric hernia repair
Number of subjects: 902
Study 22580941 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall recurrence after incisional hernia repair
Number of subjects: 902
Study 22581378 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental support
Number of subjects: 33
Study 22581378 — intervention group
Group type: EXPERIMENTAL
Intervention: Support from partners and families
Number of subjects: 33
Study 22581378 — intervention group
Group type: EXPERIMENTAL
Intervention: Racial/ethnic differences in mobilizing support
Number of subjects: 33
Study 22581378 — intervention group
Group type: EXPERIMENTAL
Intervention: Identifying support needs and expectations
Number of subjects: 33
Study 22581488 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula™ balloon-expandable renal stent
Number of subjects: 100
Study 22582313 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher individual SES (1-standard deviation increase)
Number of subjects: 284
Study 22582313 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher neighborhood SES (1-standard deviation increase)
Number of subjects: 284
Study 22582313 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher neighborhood SES (controlling for individual SES)
Number of subjects: 284
Study 22583155 — intervention group
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Number of subjects: 0
Study 22583155 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 22583335 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilonacept (320 mg loading dose followed by 160 mg weekly for up to 1 year)
Number of subjects: 8
Study 22583335 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilonacept
Number of subjects: 8
Study 22586008 — intervention group
Group type: EXPERIMENTAL
Intervention: Laxative-free computed tomographic colonography (CTC)
Number of subjects: 605
Study 22586008 — intervention group
Group type: COMPARATOR
Intervention: Optical colonoscopy (OC)
Number of subjects: 605
Study 22586182 — intervention group
Group type: EXPERIMENTAL
Intervention: FCR (fludarabine, cyclophosphamide, rituximab)
Number of subjects: 73
Study 22586182 — intervention group
Group type: EXPERIMENTAL
Intervention: (90)YFC (90yttrium ibritumomab tiuxetan added to FCR)
Number of subjects: 73
Study 22586182 — intervention group
Group type: COMPARATOR
Intervention: FCR
Number of subjects: 73
Study 22586182 — intervention group
Group type: COMPARATOR
Intervention: (90)YFC
Number of subjects: 73
Study 22586466 — intervention group
Group type: EXPERIMENTAL
Intervention: Overfeeding (+1040 ± 100 kcal/day, 46 ± 1% of energy from fat)
Number of subjects: 40
Study 22586466 — intervention group
Group type: EXPERIMENTAL
Intervention: Overfeeding
Number of subjects: 40
Study 22587415 — intervention group
Group type: EXPERIMENTAL
Intervention: LIFEspan Model
Number of subjects: 0
Study 22587481 — intervention group
Group type: EXPERIMENTAL
Intervention: DPSGC 25 mg
Number of subjects: 73
Study 22587481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 22589436 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral minocycline 100 mg twice daily for 6 months
Number of subjects: 5
Study 22589446 — intervention group
Group type: COMPARATOR
Intervention: Fourier-domain optical coherence tomography (FD-OCT) measurements in MS patients with optic neuritis
Number of subjects: 192
Study 22589446 — intervention group
Group type: COMPARATOR
Intervention: Fourier-domain optical coherence tomography (FD-OCT) measurements in MS patients without optic neuritis
Number of subjects: 192
Study 22589446 — intervention group
Group type: COMPARATOR
Intervention: Fourier-domain optical coherence tomography (FD-OCT) measurements in NMO patients
Number of subjects: 192
Study 22589446 — intervention group
Group type: COMPARATOR
Intervention: Fourier-domain optical coherence tomography (FD-OCT) measurements in LETM patients
Number of subjects: 192
Study 22589446 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourier-domain optical coherence tomography (FD-OCT) measurements in healthy controls
Number of subjects: 192
Study 22589446 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between OCT and visual field (VF) findings in NMO/LETM and MS
Number of subjects: 192
Study 22590502 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg DNA
Number of subjects: 0
Study 22590502 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg DNA
Number of subjects: 0
Study 22590502 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg DNA
Number of subjects: 0
Study 22590502 — intervention group
Group type: EXPERIMENTAL
Intervention: DermaVir immunization
Number of subjects: 0
Study 22591622 — intervention group
Group type: EXPERIMENTAL
Intervention: ASV-CO2
Number of subjects: 15
Study 22591622 — intervention group
Group type: EXPERIMENTAL
Intervention: ASV-CO2-O2
Number of subjects: 15
Study 22591622 — intervention group
Group type: COMPARATOR
Intervention: Pressure Support Ventilation
Number of subjects: 15
Study 22592608 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
Number of subjects: 0
Study 22592608 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of blinatumomab
Number of subjects: 0
Study 22594355 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of copeptin and cTnI
Number of subjects: 641
Study 22594355 — intervention group
Group type: COMPARATOR
Intervention: cTnI alone
Number of subjects: 641
Study 22594491 — intervention group
Group type: EXPERIMENTAL
Intervention: GRAZAX(®) (Phleum Pratense, 75,000 SQ-T/2,800 BAU), administered as one tablet daily for at least 4 months before the pollen season and maintained throughout the season.
Number of subjects: 628
Study 22595848 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation therapy followed by total mesorectal excision
Number of subjects: 95
Study 22595848 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligonucleotide array-based comparative genomic hybridization
Number of subjects: 95
Study 22595848 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model for lymph node metastasis
Number of subjects: 95
Study 22599356 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted hypoglossal neurostimulation (THN) therapy with the aura6000™ System
Number of subjects: 14
Study 22605616 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivantinib (ARQ 197) 120, 240, 360, and 480 mg BID plus erlotinib 150 mg QD
Number of subjects: 32
Study 22605616 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivantinib (ARQ 197) 360 mg BID plus erlotinib 150 mg QD
Number of subjects: 32
Study 22605650 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivantinib 120 mg orally twice daily, then 360 mg twice daily per protocol amendment
Number of subjects: 47
Study 22605655 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine
Number of subjects: 0
Study 22605655 — intervention group
Group type: EXPERIMENTAL
Intervention: Dersalazine sodium
Number of subjects: 0
Study 22605655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22605655 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression analysis
Number of subjects: 0
Study 22607272 — intervention group
Group type: EXPERIMENTAL
Intervention: Caries experience in first graders
Number of subjects: 485
Study 22607272 — intervention group
Group type: EXPERIMENTAL
Intervention: Caries experience in second graders
Number of subjects: 485
Study 22607272 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealant prevalence in first graders
Number of subjects: 485
Study 22607272 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealant prevalence in second graders
Number of subjects: 485
Study 22607272 — intervention group
Group type: COMPARATOR
Intervention: Statistical significance of caries experience
Number of subjects: 485
Study 22607892 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese women with PCOS (OP)
Number of subjects: 60
Study 22607892 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean women with PCOS (LP)
Number of subjects: 60
Study 22607892 — intervention group
Group type: COMPARATOR
Intervention: Lean controls (LC)
Number of subjects: 60
Study 22607892 — intervention group
Group type: COMPARATOR
Intervention: Obese controls (OC)
Number of subjects: 60
Study 22608106 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 10 μg BID
Number of subjects: 155
Study 22608261 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised accelerated radiotherapy (INDAR) with a mean lung dose (MLD) of 19 Gy, spinal cord 54 Gy, brachial plexus 66 Gy, central structures 74 Gy, total dose between 51 and 69 Gy delivered in 1.5 Gy BID up to 45 Gy followed by 2 Gy QD, starting at the 2nd or 3rd course of chemotherapy
Number of subjects: 137
Study 22608261 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised accelerated radiotherapy (INDAR)
Number of subjects: 137
Study 22608338 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg twice daily (recommended phase 2 dose)
Number of subjects: 184
Study 22608338 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg twice daily (in patients with Val600Glu BRAF-mutant melanoma)
Number of subjects: 184
Study 22608338 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg twice daily (in patients with Val600 BRAF-mutant melanoma)
Number of subjects: 184
Study 22608338 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib (in patients with melanoma and untreated brain metastases)
Number of subjects: 184
Study 22608338 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib (in patients with BRAF-mutant non-melanoma solid tumours)
Number of subjects: 184
Study 22609885 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-transplantation iron chelation
Number of subjects: 0
Study 22610494 — intervention group
Group type: COMPARATOR
Intervention: Dictation
Number of subjects: 7000
Study 22610494 — intervention group
Group type: COMPARATOR
Intervention: Structured documentation
Number of subjects: 7000
Study 22610494 — intervention group
Group type: COMPARATOR
Intervention: Free text documentation
Number of subjects: 7000
Study 22612475 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary phthalate metabolites (12 phthalate metabolites including MEP, MnBP, MiBP, MBzP, MEHP, MEHHP, MEOHP, MECPP, MiNP, MHiNP, MiONP, MCiOP)
Number of subjects: 555
Study 22614181 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy after neoadjuvant sunitinib
Number of subjects: 22
Study 22614181 — intervention group
Group type: COMPARATOR
Intervention: Open radical nephrectomy for non-metastatic disease
Number of subjects: 22
Study 22614730 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal long-term electrocardiography
Number of subjects: 0
Study 22614730 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 22614770 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-onset mut patients (n = 21)
Number of subjects: 43
Study 22614770 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-onset mut patients (n = 6)
Number of subjects: 43
Study 22614770 — intervention group
Group type: EXPERIMENTAL
Intervention: cblA patients (n = 7)
Number of subjects: 43
Study 22614770 — intervention group
Group type: EXPERIMENTAL
Intervention: cblB patients (n = 6)
Number of subjects: 43
Study 22614770 — intervention group
Group type: EXPERIMENTAL
Intervention: mut patients diagnosed prenatally or by newborn screening (n = 3)
Number of subjects: 43
Study 22614770 — intervention group
Group type: COMPARATOR
Intervention: Hyperammonemia at diagnosis
Number of subjects: 43
Study 22614770 — intervention group
Group type: COMPARATOR
Intervention: Presence of a seizure disorder
Number of subjects: 43
Study 22614770 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal testing (n = 10)
Number of subjects: 43
Study 22614770 — intervention group
Group type: EXPERIMENTAL
Intervention: Processing speed
Number of subjects: 43
Study 22614885 — intervention group
Group type: EXPERIMENTAL
Intervention: cART (nevirapine, 3TC with either zidovudine or stavudine)
Number of subjects: 529
Study 22615311 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of 30-μg 2009 Novartis pH1N1 monovalent vaccine (Fluvirin)
Number of subjects: 155
Study 22615311 — intervention group
Group type: EXPERIMENTAL
Intervention: Second vaccination for those lacking seroresponse or seroprotection after first vaccination
Number of subjects: 155
Study 22615311 — intervention group
Group type: EXPERIMENTAL
Intervention: First vaccination
Number of subjects: 155
Study 22615311 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of double-strength pH1N1 vaccine
Number of subjects: 155
Study 22615340 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological antiplatelet drug responsiveness (specific and aggregation-based assays)
Number of subjects: 771
Study 22615340 — intervention group
Group type: COMPARATOR
Intervention: Common cardiovascular risk factors (hypertension, smoking, older age, elevated low-density lipoprotein cholesterol)
Number of subjects: 771
Study 22615340 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary endpoint (MACEs)
Number of subjects: 771
Study 22619284 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational pump (intrapericardially positioned, continuous-flow centrifugal pump)
Number of subjects: 639
Study 22619284 — intervention group
Group type: COMPARATOR
Intervention: Commercially available pump (control group)
Number of subjects: 639
Study 22619284 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational pump
Number of subjects: 639
Study 22619884 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybridization real time PCR for 23S rRNA gene detection
Number of subjects: 200
Study 22619884 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin resistance detection
Number of subjects: 200
Study 22619884 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin susceptibility determined by E-test
Number of subjects: 200
Study 22619884 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of mutation gene A2142G
Number of subjects: 200
Study 22619884 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of multiple mutations (G2111A, A2115G, A2144G)
Number of subjects: 200
Study 22619884 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance prevalence for other antibiotics
Number of subjects: 200
Study 22621223 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine pre-/postnatal lactation consultant (LC) support
Number of subjects: 67
Study 22621223 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic prompts (EP) guiding providers to discuss breastfeeding
Number of subjects: 67
Study 22621223 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (LC+EP)
Number of subjects: 67
Study 22621223 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 67
Study 22621246 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation (fish oil capsules providing 1.14g DHA and 1.56g EPA for 12 weeks)
Number of subjects: 20
Study 22622425 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-IL-17 receptor antibody AMG 827
Number of subjects: 0
Study 22622425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22622497 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home short daily hemodialysis (6 times per week)
Number of subjects: 291
Study 22623056 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-0152
Number of subjects: 0
Study 22623056 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality control samples at 0.0600, 2.00 and 8.00 ng/mL
Number of subjects: 0
Study 22623056 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-0152 in human plasma
Number of subjects: 0
Study 22623056 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-0152 in whole blood
Number of subjects: 0
Study 22623715 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT
Number of subjects: 887
Study 22623715 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI
Number of subjects: 887
Study 22623715 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT and hs-cTnI
Number of subjects: 887
Study 22624038 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent systemic inflammation in COPD patients
Number of subjects: 1755
Study 22624038 — intervention group
Group type: COMPARATOR
Intervention: Non-inflamed COPD patients
Number of subjects: 1755
Study 22626269 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-guided HIFU ablation (Sonalleve 1.5T; Philips Medical Systems, Vantaa, Finland)
Number of subjects: 11
Study 22626609 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (boceprevir, peginterferon, and ribavirin) after 4 weeks of peginterferon and ribavirin for a total treatment duration of 28-48 weeks.
Number of subjects: 0
Study 22626609 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon and ribavirin for 48 weeks (control group).
Number of subjects: 0
Study 22626819 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI (Body Mass Index)
Number of subjects: 445
Study 22626819 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline F(2)-isoprostane
Number of subjects: 445
Study 22626819 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative F(2)-isoprostane
Number of subjects: 445
Study 22626819 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative PAI-1 (plasminogen activator inhibitor-1)
Number of subjects: 445
Study 22626819 — intervention group
Group type: EXPERIMENTAL
Intervention: F(2)-isoprostanes (as a mediator)
Number of subjects: 445
Study 22626819 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 445
Study 22626819 — intervention group
Group type: EXPERIMENTAL
Intervention: PAI-1
Number of subjects: 445
Study 22627070 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-polypectomy surveillance colonoscopy
Number of subjects: 902
Study 22627070 — intervention group
Group type: COMPARATOR
Intervention: High-volume workload centres
Number of subjects: 902
Study 22627070 — intervention group
Group type: COMPARATOR
Intervention: Centres providing written recommendation on surveillance interval
Number of subjects: 902
Study 22627070 — intervention group
Group type: COMPARATOR
Intervention: Surveillance examinations performed within the national screening programme
Number of subjects: 902
Study 22627182 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg alone
Number of subjects: 24
Study 22627182 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg with lopinavir/ritonavir 400 mg/100 mg
Number of subjects: 24